Arovella Therapeutics Ltd has released a press release.
ZolpiMist Update
Filed with ASX ·
On 6ix: 6ix.com/news/zolpimist-update-1
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- iNKT cell therapy platform update
- SUDA appoints new cell and gene therapy manufacturing expert
- Disclosure Document Prospectus $3.65m
- SUDA Placement Raises $3.65m
- Investor Presentation incorporating iNKT Cell Platform
Later from Arovella Therapeutics
- SUDA signs Licence and Distribution Agreement with STADA
- Dr Reuben Benjamin Appointed to SUDA iNKT Cell Therapy SAB
- GM presentation
- Chile Ministry of Health Approval Granted for ZolpiMist
- Arovella licences novel monoclonal antibody from MD Anderson
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics